Business Wire

Vistra Announces New Chief Executive Officer and Chief Financial Officer Appointments

Share

Vistra, a leading global trust, fund administration and corporate services provider, today announced the appointment of Alan Brown as Group Chief Executive Officer (CEO) and Geoff Weir as Group Chief Financial Officer (CFO). Alan and Geoff will join Vistra in April.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305005391/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alan Brown, Group Chief Executive Officer, Vistra. (Photo: Business Wire)

Based in Vistra’s headquarters in Hong Kong, both Alan and Geoff will also join the company’s Board. Their appointments are subject to regulatory approval. Simon Hinshelwood, who has been leading the business as the Executive Chairman, will resume his Non-Executive Chairman role on the Board.

Alan has extensive experience in leading global organisations, in particular, businesses going through significant transformations. He has worked across a number of industries and has lived and worked in the UK, Europe, and Asia – with particularly strong China experience.

He was most recently CEO of ASCO Group – an Aberdeen, Scotland headquartered global oil and gas services company. Prior to this, Alan held the CEO position at Rentokil Initial and was CFO at Imperial Chemical Industries (which was acquired by Akzo Nobel in 2007), and spent 25 years at Unilever in various roles in the UK and Europe, before heading up Unilever’s operations in China and Taiwan.

Geoff has held a number of group CFO roles with global companies, including Scotts Philips Associates, Exridge, Digicel, and most recently Sinar Mas in Indonesia. He has extensive experience across strategy, planning, operations, M&A, compliance, and risk management in multiple sectors. He is passionate about delivering results and has had great success in driving change, accelerating growth and delivering value in complex multinational businesses.

Commenting on the appointments, Simon Hinshelwood said, “Vistra has been on a rapid growth journey, expanding from a local company operating in five markets 10 years ago, to a truly global organisation with over 4,300 employees in 46 jurisdictions. I am confident that Alan and Geoff’s strong track record and expertise will enable Vistra to achieve its continuing growth ambitions and I look forward to working with them both.”

Alan Brown said, “I am delighted to be joining Vistra with the opportunity to lead the company in the next stage of its exciting growth and transformation journey. I look forward to working with Simon, the Board, and our colleagues across the globe to maximise the opportunity the organisation has for both our clients and employees.”

About Vistra
Ranked in the top three corporate service providers globally, Vistra is a versatile group of professionals, providing a uniquely broad range of services and solutions. Our capabilities span across company formations to trust, fiduciary, private client services, and fund administration. Vistra employs over 4,300 employees across 46 jurisdictions. For more information, please visit www.vistra.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Kate Chan, Communications Manager
media.enquiries@vistra.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 09:00:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 23:05:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 19:43:00 EET | Press release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue

LambdaTest Unveils Next-Generation SmartUI Experience for Visual Testing23.12.2024 18:00:00 EET | Press release

LambdaTest, a leading cloud-based unified testing platform has announced the general availability of its reimagined SmartUI screenshot page. This new update is all set to transform visual testing workflows, delivering a seamless, intuitive, and powerful experience tailored to the needs of testers and developers worldwide. The redesigned SmartUI interface introduces groundbreaking enhancements that prioritize user efficiency and precision. From the new pinch-to-zoom functionality for precise screenshot inspection to a streamlined navigation system featuring a side drawer for quick browsing, every detail has been thoughtfully crafted to improve productivity. The refreshed design also offers a cleaner, more spacious layout, ensuring that users can focus on what matters most—their screenshots. Smarter workflows now empower users with an intuitive grouping of related functions, while effortless variant switching simplifies the process of comparing test results. The upgraded keyboard shortcu

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases23.12.2024 14:00:00 EET | Press release

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. Fujirebio and Eisai have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer’s disease (AD). The two companies have agreed to move forward with their partnership based on the shared understanding that the development and commercialization of diagnostic methods for neurodegenerative diseases can be accelerated by integrating the long-standing respective expertise of Fujirebio, which has experience in the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye